Prof. Jean Paul Thiery, Biosyngen’s Chief Scientist, is ranked among the

World’s Top 2% Clinical Scientists 2022

Professor Jean Paul Thiery, Biosyngen’s Chief Scientist and Chairman of Scientific Advisory Board, is featured in the World’s Top 2% Clinical Scientists 2022.  Published by John P.A.Joannidis’ of Stanford University, this ranking recognizes impactful and influential clinical researchers around the world. It is an honor that Prof. Jean Paul Thiery is ranked 2^nd in the field of Clinical Medicine.

[List link ] https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw/4

The list is updated yearly since its first publication in 2018. Consideration for ranking is based on bibliometric information contained in the Scopus database consisting of almost 9 million scientists deemed to be active and productive in research, in 22 scientific fields and 176 sub-fields, worldwide. Criteria of ranking are h-index, co-authorship adjusted hm-index, citation to papers in different authorship positions and a composite indicator (c-score).

Prof. Jean Paul Thiery is among the first to propose that epithelial-mesenchymal transition (EMT) is a crucial mechanism for progression of carcinoma. At the age of 75, he is an active learner, still consuming literature and experimenting in the lab regularly. Prof. Jean Paul Thiery is a role model to researchers in Biosyngen, working together with them to develop cell therapy pipeline targeting solid and blood cancers. Our heartiest congratulations! Looking forward to continuing in our fruitful journey with Prof. Jean Paul Thiery and in achieving breakthrough benefit to human health.